Nexviazyme (avalglucosidase alfa) for treating Pompe Disease. This recommendation is for both infantile onset Pompe (IOPD) and Late onset Pompe (LOPD). Until now, only infants have been eligible ...

The drug was registered in the US last year as Nexviazyme. It is an updated version of Sanofi's blockbuster Myozyme/Lumizyme (alglucosidase alfa) therapies for Pompe, but is designed to be more ...

Her son is on Nexviazyme and used to be on Lumizyme, neither of which come from Canada. There is also not an alternative for these medications, she told the council. Meghan Dudenhoeffer said she ...

Altuviiio was approved in the EU in the second quarter. New drug, Nexviazyme/Nexviadzyme recorded sales of €163 million, up 53.6% year over year. While sales were strong in Europe and the Rest ...

Sanofi is already a big player in the Pompe disease market with injectable drugs like Nexviazyme and Myozyme/Lumizyme, but has now set its sights on an oral drug candidate from Maze Therapeutics.